Chemoprotective effects of plasma derived from mice of different ages and genders on ovarian failure after cyclophosphamide treatment

Soghra Bahmanpour,Nehleh Zarei-Fard,Eisa Moradiyan,Farzaneh Dehghani

doi:10.1186/s13048-020-00735-3

Soghra Bahmanpour, Nehleh Zarei-Fard + Show 2 more

Open Access

https://doi.org/10.1186/s13048-020-00735-3

Copy DOI

Abstract

BackgroundPremature ovarian failure is one of the major side effects of chemotherapy drugs. Blood plasma contains several factors that might lead to the repair of different tissues.ObjectiveThe chemoprotective effects of plasma derived from mice with different ages and genders were assessed on ovarian tissue in cyclophosphamide-treated mice.MethodsForty-two adult female mice were divided into six groups as follows: (A) control; (B) 0.9% sodium chloride as vehicle; (C) cyclophosphamide; (D) cyclophosphamide + young male blood plasma; (E) cyclophosphamide + old male blood plasma; (F) cyclophosphamide + young female blood plasma. Ovarian failure was induced by injecting cyclophosphamide. On the 1st day, three groups received simultaneous injections of 150 μL intraperitoneal and 70 μL intravenous plasma derived from mice of different ages and genders. Each plasma type (150 μL) was then injected intraperitoneally every other 3 days for 19 days. On day 21, the dissected ovaries were stained for stereological analysis. Also, estrogen and progesterone levels were measured.ResultsCyclophosphamide had damaging effects on ovarian parameters and led to reduced hormone levels in comparison with the control group. However, treating with young female and, old male blood plasma, to a lesser degree, showed beneficial effects on the number of primordial follicles, pre-antral follicles, and granulosa cells. Also, these two treatments had protective effects on the volume of ovarian parameters as well as estrogen and progesterone levels in comparison with the cyclophosphamide group (P < 0.05).ConclusionPlasma derived from mice of different ages and genders can ameliorate premature ovarian failure against the adverse effects of cyclophosphamide.

Highlights

Premature ovarian failure (POF) is a complex heterogeneous disorder, characterized by the cessation of the menstrual cycle, reduced estrogen and progesterone levels as well as depletion of all types of ovarian follicles especially primordial follicles in women < 40 years
The ovarian weight of the groups treated with old male blood plasma (P = 0.032) and young female blood plasma (P = 0.023) had significantly increased compared to the CYC treated group (Fig. 1C)
The ovarian volume was significantly increased in the young female (p = 0.033) and old male (P = 0.039) plasma-treated groups compared to the CYC-induced ovarian failure group (P = 0.011)

Summary

Introduction

Premature ovarian failure (POF) is a complex heterogeneous disorder, characterized by the cessation of the menstrual cycle, reduced estrogen and progesterone levels as well as depletion of all types of ovarian follicles especially primordial follicles in women < 40 years. It was shown that CYC led to ovarian toxicity by induction of different signaling pathways which are involved in the ovarian follicle apoptosis, resulting in an increase in the incidence of POF and infertility [8,9,10]. The protective roles of the co-administration of gonadotropinreleasing hormone (GnRH) agonists or other chemotherapy drugs such as imatinib with CYC on ovarian reserve have been reported previously [8, 10,11,12,13,14]. Ovarian protection by GnRH agonist administration during chemotherapy treatment has been recommended by the American Society for Reproductive Medicine, its protective effects are controversial and not generalizable to all patients [14]. Premature ovarian failure is one of the major side effects of chemotherapy drugs. Blood plasma contains several factors that might lead to the repair of different tissues

Methods

Results

Discussion

Conclusion